The prognostic role of echocardiographic parameters in ischemic stroke patients with atrial fibrillation.
Abstract
Background
Concomitant cerebral small vessel disease (cSVD) in stroke patients with atrial fibrillation (AF) is associated with an unfavourable outcome, but the additional prognostic value of echocardiographic parameters remains unclear.
Methods
We included consecutive patients with recent AF-associated ischemic stroke (IS) or transient ischemic attack (TIA) who underwent echocardiography and brain MRI from the prospective Novel Oral Anticoagulants in Ischemic Stroke Patients registry. We examined associations of left atrial and ventricular echocardiographic parameters with a primary composite outcome (recurrent IS; intracranial hemorrhage, all-cause death) and its components as secondary outcomes, using unadjusted and adjusted (age, sex, modified CHA2DS2VASc-Score, hyperlipidemia, oral anticoagulation before/after stroke, MRI markers of cSVD) Cox regression. Associations between echocardiographic parameters and MRI markers of cSVD were analyzed using logistic regression.
Results
We included 690 patients (median age 80, 45% female) with a total follow-up of 1084 patient-years. In unadjusted analyses, left ventricular hypertrophy (LVH) was associated with the composite outcome (HR 1.44 [1.05-1.97]) and all-cause death (HR 1.95 [1.33-2.84]), neither association persisted after adjustment (aHR 1.04 [0.74-1.46]; aHR 1.29 [0.85-1.96]) Reduced ejection fraction and concentric/eccentric hypertrophy were associated with all-cause death in unadjusted analysis only. No echocardiographic parameter was associated with recurrent IS. Left atrial dilatation (OR 1.96 [1.32-2.91]) and concentric hypertrophy were associated (OR 1.68 [1.08-2.62]) with white matter hyperintensities extent in unadjusted but not in adjusted analyses.
Conclusion
In stroke patients with AF, structural changes of the left ventricle might be considered as indicator but not independent predictor of future cerebrovascular events or death. CLINICAL TRIAL REGISTRATION NCT03826927.